Wellington Management Group LLP Invests $868,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)

Wellington Management Group LLP purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 14,949 shares of the company’s stock, valued at approximately $868,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. KBC Group NV boosted its stake in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics during the 2nd quarter worth $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the 3rd quarter valued at $213,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KROS has been the subject of a number of analyst reports. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 12th. Oppenheimer lowered their price target on Keros Therapeutics from $102.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday. Scotiabank cut their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research report on Friday, December 13th. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Bank of America lowered their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Stock Down 1.2 %

Shares of KROS stock opened at $16.92 on Friday. The company has a market capitalization of $685.38 million, a price-to-earnings ratio of -3.25 and a beta of 1.20. Keros Therapeutics, Inc. has a 12-month low of $15.67 and a 12-month high of $73.00. The firm has a fifty day moving average of $55.83 and a 200-day moving average of $51.81.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.33) earnings per share. On average, equities analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.